140 related articles for article (PubMed ID: 8251097)
1. Role of the Institutional Review Board in clinical trials.
Skolnick BE
Epilepsy Res Suppl; 1993; 10():193-200. PubMed ID: 8251097
[No Abstract] [Full Text] [Related]
2. Preparing for an FDA audit.
Barnes D
Epilepsy Res Suppl; 1993; 10():245-50. PubMed ID: 8251103
[No Abstract] [Full Text] [Related]
3. The role of the pharmacist in investigational AED trials.
Graves NM
Epilepsy Res Suppl; 1993; 10():201-9. PubMed ID: 8251098
[No Abstract] [Full Text] [Related]
4. Study population selection.
Treiman DM
Epilepsy Res Suppl; 1993; 10():125-35. PubMed ID: 8251088
[No Abstract] [Full Text] [Related]
5. Ethical considerations.
Treiman DM
Epilepsy Res Suppl; 1993; 10():137-48. PubMed ID: 8251089
[No Abstract] [Full Text] [Related]
6. Sources of variability in clinical trials of new drugs for epilepsy.
Leppik IE
Epilepsy Res Suppl; 1993; 10():157-66. PubMed ID: 8251091
[No Abstract] [Full Text] [Related]
7. European investigational antiepilepsy drug trials.
Sussman NM
Epilepsy Res Suppl; 1993; 10():149-55. PubMed ID: 8251090
[No Abstract] [Full Text] [Related]
8. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
Browne TR
Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
[No Abstract] [Full Text] [Related]
9. Visit management: reducing unnecessary paperwork.
Salzmann JK
Epilepsy Res Suppl; 1993; 10():223-31. PubMed ID: 8251100
[No Abstract] [Full Text] [Related]
10. Protocol design.
Wilensky AJ
Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086
[No Abstract] [Full Text] [Related]
11. External influences on protocol design.
Spilker B
Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
[No Abstract] [Full Text] [Related]
12. Obstacles encountered in designing antiepileptic drug trials.
French JA
Epilepsy Res Suppl; 1993; 10():81-9. PubMed ID: 8251107
[No Abstract] [Full Text] [Related]
13. The domestic drug regulatory process: why time is of the essence.
Katz R
Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
[No Abstract] [Full Text] [Related]
14. [Responsibilities of ethics committees].
von Bergmann K
Med Klin (Munich); 2000 May; 95(1 Spec No):15-7. PubMed ID: 10851843
[TBL] [Abstract][Full Text] [Related]
15. Patient recruitment and compliance issues in clinical trials.
Cramer JA
Epilepsy Res Suppl; 1993; 10():211-22. PubMed ID: 8251099
[No Abstract] [Full Text] [Related]
16. Ethical and institutional review board issues.
Skolnick BE
Adv Neurol; 1998; 76():253-62. PubMed ID: 9408484
[TBL] [Abstract][Full Text] [Related]
17. Protection of human subjects; informed consent; standards for institutional review boards for clinical investigations--FDA. Proposed rule.
Fed Regist; 1988 Nov; 53(218):45678-82. PubMed ID: 10290533
[TBL] [Abstract][Full Text] [Related]
18. Institutional review boards and bioethics committees: their role in ensuring ethical home care research.
Cary AH
Home Care Econ; 1987; 1(4):113-8. PubMed ID: 10285378
[No Abstract] [Full Text] [Related]
19. Interview with Gary L. Yingling, J.D.
Yingling GL
Qual Manag Health Care; 1999; 7(3):45-7. PubMed ID: 10537462
[No Abstract] [Full Text] [Related]
20. Antiepileptic drug development program.
Porter RJ
Prog Clin Biol Res; 1983; 127():53-66. PubMed ID: 6351101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
